“In the wake of record-breaking global warming reported in 2023, we’re calling on the industry and businesses around the world to come together to drive meaningful change against the climate crisis. The technology exists today to dramatically reduce emissions and to bridge progress and sustainability,” said Peter Herweck, CEO of Schneider Electric. “Only through innovation and collaboration can we unlock new opportunities for digitalization, electrification and decarbonization that creates lasting impact. Because together, we can turn ambition into action.”

Herweck will address Innovation Summit Paris attendees today, calling on global leaders from across industries to accelerate their digital transformation journeys and embrace technology and partnerships to productivity and sustainability goals.

Inaugurated in 2016, Schneider Electric’s Innovation Summits showcase the company’s latest innovations, solutions, and partnerships that drive the future of automation, electrification, and digitalization. This year, it gathers customers, partners, and industry leaders in Paris for a two-day program of plenaries, breakout sessions, roundtables, deep dives, networking, and exhibition hall tours.

New Solutions for Greater Impact

Schneider Electric is unveiling new solutions designed to help companies strategize, digitalize, and decarbonize their operations, and accelerate sustainability commitments, including:

• CONNECT: an agnostic, end-to-end, industrial intelligence platform that integrates engineering and operational data to provide visibility across the entire value chain and ecosystem. Connecting clients to Schneider Electric, AVEVA, etap, RIB and other third-party software providers, CONNECT leverages AI and the intelligent digital twin to empower businesses to unlock efficiencies and drive sustainability for responsible growth. 
• Resi9 Energy Center: a retrofit, compact intelligent electrical panel for homes that integrates with existing panels, ensuring secure supply and distribution of electricity. As more homes are electrified and equipped with renewables like solar, EVs and microgrids—and as more homeowners are becoming prosumers, both producing and consuming energy— electrical panels are challenged with increased and complex loads. Resi9 Energy Center seamlessly integrates across home energy management systems to enable control and customization for greater home energy management and optimization.
• eMobility portfolio expansion: While EV adoption is growing exponentially, only about half (51%) of EV owners worldwide have a charger at home. Schneider Charge offers a state-of-the-art home charging solution that is robust, cost-effective and simple to install. And for fleet and charge point operators, EcoStruxure EV Advisor and EVLink Pro DC 180 kW offer the latest in electric vehicle (EV) charging and management. EVLink Pro DC fast-charging station maximizes energy efficiency while minimizing electrical costs. EcoStruxure EV Advisor software-as-a-service helps to improve reliability and performance of charging points by providing operators visibility into charging performance, energy consumption, and operational efficiency. In combination, they offer customers across fleet, car parks, commercial and residential buildings a flexible, open source, end-to-end solution for EV charging. Reliable charging infrastructure is critical to accelerating EV adoption, but it requires skilled labor to install and maintain it. Today Schneider Electric also announced the expansion of its North America partner, Qmerit, the leading provider of distributed workforce management for EV charging, to European markets.

Collaborations for Meaningful Change

Partnerships and collaboration across industries and supply chains will be imperative to tackling the climate crisis. Schneider Electric is uniting industry leaders and value chains to drive greater decarbonization and sustainability, through:

• Sustainability impact: Schneider Electric’s Sustainability Impact Award program recognizes partners, customers, and suppliers who are decarbonizing their own operations and that of their customers. By showcasing successes that reduce emissions, improve energy efficiency, and implement digital technologies, companies can learn from each other to drive wider impact and further innovation.
• Supply chain decarbonization: An expansion of Schneider’s suite of supply chain decarbonization programs, Materialize aims to unite leading critical resources and materials companies to implement Scope 3 decarbonization strategies and facilitate the transition to a low-carbon economy. Suppliers can participate in utility scale, renewable power purchase agreements (PPAs) to reduce carbon emissions across global value chains, which typically account for more than 70% of a business’s carbon footprint. The programs continue to expand with Edwards, a global leader of vacuum and abatement solutions, joining Schneider’s Catalyze program that seeks to decarbonize semiconductor value chains.
• Data center partnerships: Schneider Electric and Digital Realty‘s new circular economy initiative builds on 20 years of expert data center partnership and is expected to help Digital Realty reduce 50%-70% of embodied carbon within its LV, MV, and three-phase UPS equipment over the next 3-5 years, while also reducing e-waste and Scope 3 emissions. In addition, Schneider Electric’s collaboration with NVIDIA —world leader in artificial intelligence computing— is set to optimize data center infrastructure and drive advancements in edge AI and digital twin technologies.

To learn more about Schneider’s Innovation Summits or to register to participate online, visit: https://www.se.com/ww/en/about-us/events/innovation-summit-world-tour.jsp

Contact:
Schneider Electric Global Media Relations
global.pr@se.com

Attachment

• Press Release_IS_Schneider Electric Begins Innovation Summit World Tour, Unveiling Latest Innovations and Collaborations.pdf

Two-Way Conversion System:
In an era where digital marketing landscapes are continuously evolving, Clixyes introduces a pioneering two-way conversion system, setting a new standard for brand engagement. This system intricately combines the outreach power of our extensive network, including social media influencers, chat groups, content sites, online forums and so on, with the direct consumer engagement capabilities of Shop Clixyes. Our proprietary platform, Shop Clixyes, featured with influencer and editor’s picks, providing a marketplace for targeted ad placements to convert site visitors directly, embodying a holistic approach to digital marketing.

Our Strength and Media Resources
Clixyes.com formidable presence in the digital marketing realm is bolstered by our expansive media resources. With over 800 cooperated brands, a network of 400,000+ social media content creators, access to 10,000+ content sites, and a global audience reach of 4 billion, clixyes.com offer unmatched opportunities for brands to amplify their visibility and influence across diverse channels and demographics.

Strategic Influencer Collaborations
Central to our success is our strategic focus on influencer collaborations. Clixyes empowers publishers and brands with professional services, extensive resources, and cutting-edge technology. Our media team works closely with publishers, providing one-on-one management and assistance to ensure fruitful partnerships with brands. This is complemented by our rich repository of brand collaborations and advanced data analysis systems, offering promotion insights that drive strategy refinement and engagement maximization.

Empowering Brands with Advanced Solutions
For brands, Clixyes provides a trifecta of benefits: Resources, Technology, and Service. By tapping into our worldwide audience and leveraging our vast network of multi-channel creators, brands can significantly expand their horizon. Our sophisticated backend analytics afford brands precise monitoring of creator data, fostering transparency and smarter campaign decisions. Furthermore, our dedication to personalized service ensures that each brand is paired with a dedicated liaison, guiding them towards achieving their marketing goals with unparalleled support.

Clixyes.com is committed to transforming the digital marketing landscape through its innovative approaches, robust analytics, and strategic collaborations. As we continue to forge paths in the digital marketing frontier, we invite brands and publishers to explore the myriad opportunities for growth and engagement that Clixyes.com offers.

For more information on how Clixyes can elevate your digital marketing strategy, please contact team@clixyes.com or visit https://network.clixyes.com/.

Leipzig, Germany, April 3, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that Dr. Thomas Lingner was appointed Chief Technology Officer and Inga Freyert was promoted to VP Quality and Regulatory Affairs.

In addition to his role at BellaSeno, Dr. Thomas Lingner is Managing Director and CSO of Genevention GmbH, a bioinformatics / software company he co-founded in 2017. Prior to this, he was Principal Bioinformatician, Microarray and Deep-Sequencing Core Facility, at the University Medical Center Göttingen. From 2008 to 2014, Thomas Lingner worked as a Post-Doctoral Researcher at the University of Göttingen, CRG Barcelona, Spain and the University of Stavanger, Norway. He holds a PhD in Bioinformatics from the University of Göttingen and a Diploma in Computer Science from the University of Bielefeld, Germany.

Inga Freyert served as BellaSeno´s Head of Quality Management since 2022 and was promoted to VP Quality Management and Regulatory Affairs in early 2024. Prior to that, she was Head of Quality Management at TimeWaver Production GmbH and quality management representative at bess pro GmbH Medical Leufen GmbH and bess medizintechnik GmbH. Before joining bess pro GmbH, Inga Freyert worked as Quality & Regulatory Specialist / Junior Q&R Manager at MagForce AG, Berlin. From 2011 to 2018, she was Head of Batch Record Review Quality Control Team at IDT Biologika GmbH, Dessau-Roßlau. She holds a Diploma in Biology from the University of Göttingen.

“We warmly welcome Dr. Thomas Lingner and Inga Freyert to their new roles at BellaSeno,” said Dr. Mohit Chhaya, CEO of BellaSeno. “Top-tier quality standards and technological leadership are at the heart of BellaSeno´s corporate identity. Therefore, the expertise of Thomas and Inga will be crucial for further advancing our leading-edge pipeline in soft and hard tissue regeneration.”

###

About BellaSeno
BellaSeno GmbH was founded in 2015 and is headquartered on the BioCity campus in Leipzig, Germany, with a subsidiary in Brisbane, Australia. The Company is developing novel resorbable soft tissue and bone reconstruction implants made by additive manufacturing (3D-printing) under ISO 13485 certification. The Company has received substantial financial support from private investors as well as from the Saxony Development Bank (SAB), the European Fund for Regional Development (EFRE), Germany´s Federal Ministry of Education and Research (BMBF) and the Australian government. The Company has been co-funded from tax resources based on the budget adopted by the members of Saxony State Parliament.

Contact BellaSeno
BellaSeno GmbH
Dr. Mohit Chhaya
mohit.chhaya@bellaseno.com
Tel.: +49 176 2283 9583

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

Warsaw, April 3, 2024. – Molecure S.A. (“Molecure”, WSE ticker: MOC), a biotechnology company that discovers and develops drugs to the clinical stage and leverages its globally unique expertise in medicinal chemistry and biology to explore and develop first-in-class small-molecule drugs that directly modulate protein activity and mRNA function to treat a range of incurable diseases, has published its 2023 annual report. The report is available at: https://molecure.com/pl/informacje-dla-inwestorow/

“2023 was an exceptional year for Molecure as we made significant progress in the development of both clinical and preclinical programmes, particularly in the area of small-molecule drugs targeting mRNA. We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure. We have made significant progress with OATD-02, a dual arginase inhibitor, and will soon begin administering the drug (at a dose of 20 mg) to a fourth cohort of patients with solid tumors. We are also seeing an increase in biomarkers suggesting a pharmacodynamic effect in the absence of significant side effects.

In 2023, our focus was also on preparing for a Phase II clinical trial for OATD 01, Molecure’s flagship clinical programme. We obtained FDA and then MHRA approval to initiate a Phase II clinical trial of OATD-01 in patients with pulmonary sarcoidosis. It is noteworthy that we went through the whole procedure very smoothly, which demonstrates the high quality of our research and documentation. We are very pleased to report that the first patient has started dosing in a clinical trial at a clinical site in the UK. OATD-01 is a first-in-class chitinase inhibitor developed by Molecure scientists for the treatment of sarcoidosis, which will be administered to placebo-controlled patients. We are shortly awaiting Phase II clinical trial approvals for OATD-01 from regulatory authorities in Denmark, France, Greece, Germany and Norway.

Last year was also a time to continue Molecure’s transformation into a cutting-edge company, applying the latest generative and predictive artificial intelligence techniques to our early drug discovery programmes, including a platform of small-molecule drugs interacting directly with mRNA targets. We achieved our first major success with Proof-of-Concept in vitro, confirming the inhibition of protein translation with compounds targeting the mRNA encoding the protein. We also adopted an approach to identifying the most promising preclinical projects, aiming to maintain a balanced portfolio of projects with strong clinical and transactional potential.

The last two years have been difficult for biotech companies due to the destabilisation of the geopolitical environment, inflation and interest rates, which slowed down partnership discussions and capital raising. Despite these difficulties, thanks to investors’ faith in the potential of our programmes, we successfully completed a capital round and raised approximately PLN 50 million in growth funding from investors through a share issue.

Our clinical development is incurring increasing costs, but we have our own funding and awarded grants that will allow us to continue with both clinical projects and those with the best earlier stage of development until at least early 2025. In parallel, we are applying for new grants to support projects and IT and computational methods, which will allow us to accelerate the development of programmes.

We are confident that pursuing our mission will open up new treatment opportunities for patients and provide a significant return on investment for shareholders. We thank you for your trust to date and encourage you to continue working with us.” – said Marcin Szumowski, CEO of Molecure S.A.

Presentation for investors

The Company’s presentation to investors will take place on 10th April 2024, at 2 pm (CEST) in an online meeting format, under the link: https://livingmedia.com.pl/live/molecure/2023-en

Selected key developments in 2023 and up to the date of publication of the financial report

• Strategy Update
  The Company’s main strategic objectives in the area of R&D and business development are:
  • Continued intensive clinical development of two key projects: completion of a Phase II study for OATD-01 in sarcoidosis and completion of a Phase I clinical trial for OATD-02 in oncology patients, with possible expansion to additional indications and combination therapies
  • Further development of early preclinical stage projects, including the identification of 1-2 advanced lead compounds (candidates for preclinical development) and the introduction of a further programme to the clinical trial stage
  • Accelerate the development of a breakthrough platform of small-molecule drugs targeting mRNA, including the achievement of in vitro PoC and the selection of lead molecules
  • Increasing the efficiency of drug discovery processes (by reducing time and cost and lowering the risk of failure) through investment in machine learning and generative artificial intelligence (GenAI) technology
  • Conclusion of at least 1 high-value partnership agreement for at least one clinical-stage project, as well as the establishment of a number of commercial collaborations, including profit-sharing, for earlier-stage programmes

Investment expenditures, among others, for the implementation of the objectives set out in the Strategy in the period from 2024 to the end of 2025 have been set at approximately PLN 150 million.

• Successful completion of a public offering (SPO)
  • Molecure has successfully raised gross proceeds of approximately PLN 50m from its public share offering from existing and new shareholders
  • The funds raised from the SPO and expected grants will be used to fund the Company’s growth plans and continue to build a balanced portfolio of breakthrough therapies including first-in-class drugs, including the completion of a Phase II study of OATD-01 in sarcoidosis and the completion of a Phase I clinical trial of OATD-02 in oncology patients, with the potential to expand into additional indications and combination therapies

• Phase II clinical trial approvals for OATD-01 and initiation of the trial
  • Molecure has received approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a Phase II clinical trial for OATD-01 in the US and UK. The proof-of-concept Phase II study is the first to administer the drug to patients with pulmonary sarcoidosis. The world’s first patient administration of chitotriosidase inhibitor 1 (CHIT1) or placebo took place in March this year at the Royal Infirmary in Edinburgh. As part of the trial, patients will take a fixed dose of 25 mg OATD-01 or placebo daily in tablet form for 12 weeks
  • Molecure has reapplied for permission to conduct a Phase II clinical trial of OATD-01 in EU countries: Denmark, France, Greece, Germany and Norway. In the previous coordinated assessment procedure, a refusal decision was issued by the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, and the effect of the refusal was that, despite receiving approval from the ethics committees in Greece, Germany, France, Denmark, Poland and Norway, it was not possible to conduct the clinical trial in the requested EU countries, as Poland was reported in the application as the rapporteur country. In the re-proceeding, Molecure proposed Denmark as a rapporteur country in the application assessment process.

• Phase I clinical trial OATD-02
  • Achieving significant progress in the clinical development of OATD-02, an oral, potent and selective first-in-class arginase (ARG1 and ARG2) inhibitor, in cancer therapies
  • March 2023 saw the administration of OATD-02 to the first oncology patient in a Phase I clinical trial to evaluate the safety, tolerability and preliminary efficacy of OATD-02 in patients with advanced and/or metastatic solid tumors
  • Continued systematic dose escalation and planned imminent commencement of administration in a fourth cohort of patients with solid tumors, to determine the maximum tolerated dose and recommended dose for the next phase of the study

• Development of the mRNA platform
  • Molecure confirms the efficacy of small molecules in inhibiting the translation of pathogenic proteins achieving a key milestone in the development of a breakthrough platform of small-molecule drugs targeting mRNAs
  • In vitro proof-of-concept (PoC) assay confirms inhibition of protein translation with compounds targeting the mRNA encoding the protein
  • The PoC stage for the first molecule developed in the mRNA platform provides evidence of the effectiveness of Molecure’s strategy to identify mRNA-binding compounds with therapeutic potential
  • The success achieved in the development of the mRNA platform increases the likelihood of signing a collaboration agreement with partners working in this area
  • Receipt of funding for a project to develop small-molecule drugs directly interacting with mRNA under the SMART pathway of the FENG programme (European Funds for a Modern Economy). The amount of funding is approximately PLN 32.5 million with a total project budget of approximately PLN 51.5 million. The project will be implemented between 2023 and 2028

• Business Development
  • In 2023, Molecure representatives held a total of 107 meetings with biotech industry representatives in Europe and the US (Basel, London, Boston, Munich), mainly with potential partners, investors and global pharmaceutical companies. OATD-01 (37 meetings), OATD-02 (25 meetings) and USP7 (23 meetings) attracted the most interest. As a result of the meetings held, the Company signed 11 non-disclosure agreements (CDAs) with interested companies. This year, representatives of the Company were present at the BIO-Europe conference in Barcelona, which took place from 18-20 March

Key organisational changes in 2023 relevant to the growth and advancement of research programme

• Appointment of Dr Samson Fung – Chief Medical Officer to the Company’s Board of Directors to support the clinical development of OATD-01 and OATD-02
• Dr Zbigniew Zasłona has been promoted to Chief Scientific Officer from his previous role as VP Research Biology. Dr Zasłona remains a member of the Board of Directors of Molecure

Summary of financial data in 2023

• Operating income of PLN 1.3 million, up from PLN 1.6 million in 2022.
• Operating expenses were PLN 23.4 million, up PLN 4.8 million from 2022, due to the progressive advancement of the Company’s programmes and pipeline expansion. Increase mainly due to an increase in salaries and wages, increasing early-stage research costs and third-party service costs
• Net loss in 2023 amounted to PLN 18.3 million compared to a net loss of PLN 15.3 million in the same period in 2022
• As at 31 December 2023, Molecure had cash and cash equivalents of nearly PLN 64 million.

As at the date of publication of the Annual Report (29 March 2024), the Company has approximately PLN 54 million at its disposal – the Company has a stable capital position necessary to continue to finance the Company’s dynamic growth. In addition, contracted grant funding for the coming years amounts to PLN 32.5 million. The Company plans to obtain further grants for projects within the framework of the pipeline developed so far.

***

About Molecure S.A.

Molecure S.A. is a biotechnology company that discovers and develops drugs to the clinical stage, using its own unique expertise in medicinal chemistry and biology to search for and develop first-in-class small-molecule drugs that, through direct modulation of previously unexplored protein and RNA targets, could provide therapies for many incurable diseases.

Molecure has generated a diverse portfolio of seven distinct programmes with the support of leading academic research institutions around the world, including Yale University, Rutgers University, the Flemish Institute for Biotechnology (VIB) in Ghent, the University of Michigan and the International Institute of Molecular and Cell Biology in Warsaw (MIBMiK).

The most advanced drug candidate developed by Molecure is OATD-01, a first-in-class CHIT1 inhibitor for the treatment of interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis, which is ready to enter Phase II clinical trials. The Phase II study in sarcoidosis patients started in Q4 2023 in the US and the UK and will also continue in the EU and Norway, after gaining the appropriate regulatory approval.

The second drug candidate is OATD-02, an oral, selective, first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, whose Phase I clinical trial has begun with first patient administration in Q1 2023.

Molecure’s headquarters and laboratories are located in Warsaw and Lodz. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

Detailed information can be found on: https://molecure.com/pl/

LinkedIn: Molecure | Twitter: @molecure_sa | YouTube: Molecure SA     

As the world transitions to net-zero emissions and scales up clean energy technologies, demand for minerals and metals will grow exponentially. To meet this demand without furthering carbon emissions, it is vital that companies collaborate to decarbonize power supply, mitigate the environmental impact of the energy-intensive processes related to these critical resources, and reduce the sector’s Scope 3 emissions.

Materialize is a continuation of Schneider Electric’s suite of supply chain decarbonization programs from its Sustainability Business consulting division, which leverage the power of supply chain cohorts for renewable energy procurement at scale. The Materialize program will encourage the wider value chain to transition to renewable energy sources by accelerating the deployment of decarbonization projects and software, improving access for suppliers to renewable energy solutions at scale, such as power purchase agreements (PPAs).

“We are delighted to launch Materialize as our latest collaborative program to reduce Scope 3 emissions. We have a strong track record of working with customers to meet their sustainability objectives, and this program will accelerate action in this sector,” said Barbara Frei, Executive Vice President, Industrial Automation at Schneider Electric. “Educating suppliers within the sector’s wider value chain on the importance of their operational models in closing net-zero ambition gaps is vital if we are to decarbonize the sector. Materialize will drive definitive next steps for the industry to lead the way.” 

Lowering emissions is a challenging task due to the complexity of the value chain, data availability and reliability, and the difficulties in defining the breadth of the sector’s Scope 3 emissions. Suppliers lack expertise in decarbonization and face barriers to progress, such as solution costs and availability. Through Materialize, experts from Schneider Electric’s Sustainability Business will simultaneously engage hundreds of industry suppliers through digital technology platforms and guide them on removing such barriers. 

Industry collaborator, Global Mining Guidelines Group (GMG), CEO Heather Ednie, said: “Through collaboration and innovation, the partnership between GMG and Schneider Electric seeks to revolutionize the mining supply chain, moving it even further toward sustainability. As GMG members push the boundaries of what is possible, Materialize will be instrumental in disseminating knowledge to the industry at large, and establishing clear pathways for it to become more sustainable.”

Materialize also has the potential to offer industries outside of the sector a way to decarbonize their broader supply chain ecosystems. by sourcing materials suppliers who prioritize sustainable and low-carbon production methods.

“Measuring scope 3 emissions shines a spotlight on supply chains and reinforces the importance of circularity. Materialize will help to further circularity in the sector and beyond, and this is something we support,” said Kunal Sinha, Global Head of Recycling at Glencore.

Schneider Electric’s other programs include Energize, a collaborative effort across the pharmaceutical industry with over 500 supplier companies already participating, and Catalyze for semiconductor companies. Both were created to engage thousands of suppliers simultaneously to drive swift and measurable action to reduce program sponsors’ Scope 3 emissions. The portfolio builds on Schneider’s foundational initiative, The Zero Carbon Project, that provides resources and guidance to program participants, encouraging ambitious decarbonization goals with a deployment action plan to achieve it.
 

Contact:
Schneider Electric Global Media Relations
global.pr@se.com

Attachment

• Schneider Electric launches Materialize program for Scope 3 decarbonization of natural resources.pdf

Unveiled at Schneider Electric’s recent Innovation Summit in Paris, this new solution marks a significant leap forward in energy management, offering enhanced safety, efficiency, and sustainability to meet the demands of the evolving energy landscape.

In a world where homes are increasingly electrified and equipped with energy production and storage technology such as solar panels, inverters and battery back-up, Schneider Electric has recognized the need for a comprehensive solution to manage the rising demand for electricity. The Resi9 Energy Center serves as the ultimate upgrade to the traditional electrical panel, addressing the challenges posed by the new energy landscape.

New era of the electrical panel

As globally we adopt more sustainable lifestyles, the electrification of our homes is expanding at a rapid rate, from the installation of solar panels and heat pumps, through to electric vehicle (EVs) chargers to power our modern-day vehicles. Prosumer households – homes that both produce and consume electricity – are increasingly common, especially with solar production.

These new technologies rely on the electrical panel, also known as the fuse box, which is at the heart of the home and acts as the gatekeeper for ensuring the safety of electrical devices and appliances. However, according to Schneider Electric’s global consumer survey carried out in 2023, almost a third of homeowners (29%) know very little about the role the electrical panel plays in their home and 16% wouldn’t know where it is located. These figures increase amongst Gen Y and Gen Z respondents – those who are becoming or will become homeowners in a time when electrification is at its highest – to 41% and 25% respectively.

It is critical for safety, and for efficacy of energy efficiency measures, that homes are equipped with the appropriate electrical panel, yet there is little awareness that becoming a prosumer or adding larger loads, such as EV chargers, could render the existing electrical panel as no longer fit for purpose.

The evolution of electrical safety – celebrating 100 years of the circuit breaker in homes

Over the past century, the electrical panel has played a crucial part in ensuring the safety of families and homes, especially through circuit breakers protecting against short circuits, overloads, and various electrical risks.

Schneider Electric, founded in 1836 and in the electrical market for close to 150 years, has continuously pioneered advancements in electrical safety. In the past 100 years of progress following the introduction of micro circuit breakers, we have seen:

1970s: New surge protection devices protected homes from lightning strikes 

1980s: Residual current devices were introduced to reduce the risk of electrocution

2000s: Arc-fault detection devices were introduced to safeguard households against fires

2018: Schneider launched PowerTag, the world’s tiniest energy sensor to understand how much electricity is consumed over the breaker or at load level

Today. Schneider Electric’s latest innovation in electrical safety and efficiency brings the electrical panel into a new era. The Resi9 Energy Center seamlessly integrates with any existing electrical panel, making it a perfect choice for retrofit and renovation projects. Equipped with high-spec hardware and state-of-the-art software, the Resi9 Energy Center provides enhanced security in the supply of electricity through various sources and its safe distribution to all electrical loads, including electric vehicle and heat pumps. All the while enabling sustainable control and customization through Schneider Electric’s all-in-one Home Energy Management app, Wiser.

Managing energy in your home becomes effortless with the Resi9 Energy Center and the Wiser Home Energy Management System. From charging your electric vehicle during off-peak hours to maximizing solar energy utilization, the Wiser Home Energy Management app puts these capabilities at your fingertips, offering real-time insights, savings tracking, and progress monitoring toward a self-sufficient home—all in one user-friendly platform.

Michael Lotfy Gierges, Executive Vice President of Global Home & Distribution at Schneider Electric, said: “The electrification of our homes is undeniably a positive step towards a more sustainable energy future. This shift, powered by renewables, enables us to tackle the 20% of global emissions produced by homes. However, as exciting as the transition to a new energy landscape is, it’s vital that safety sits at its core.

“Utilizing our 188 years of experience – 150 of which have been dedicated to the electrical market –the Resi9 Energy Center represents a true evolution of the electrical panel, and we are proud to introduce a solution that supports the electrification of homes while keeping safety, resilience, efficiency, and sustainability at the forefront.”

Contact:
Schneider Electric Global Media Relations
global.pr@se.com

Attachment

• Press Release_IS_Schneider Electric Unveils Resi9 Energy Center Retrofit Innovation for Prosumer Homes.pdf

The company’s three new entries in the eMobility space include EVlink Pro DC 180kW charging stations, its scalable charging solution for commercial environments; Schneider Charge, its new EV charging station for homes; and EcoStruxure for eMobility EV Advisor, an EV charging management platform which will improve charging station uptime and performance.

Unveiled today at its annual Innovation Summit, Schneider Electric’s new solutions will allow operators to effectively manage, monitor and maintain reliable charging infrastructure, helping to meet the forecast need for hundreds of millions of charging connectors by 2040.

Managing charging networks, minimizing downtime

More than 60% of consumers globally cite concerns over charging infrastructure as a significant barrier to EV uptake. EcoStruxure for eMobility EV Advisor addresses these concerns by minimizing charge station downtime. With real-time monitoring, analytics and remote management capabilities, this new software-as-a-service offer gives charge station operators valuable insights into performance, energy consumption and operational efficiency. Issues can then be swiftly addressed, helping to maintain power reliability and provide a convenient experience for EV drivers.

EV Advisor helps business owners and operators reduce operational costs and time dedicated to managing EV charging systems. Businesses can control and optimize system energy use across multiple sites, improving revenue streams from charging.

A connected interface also allows for more efficient collection of payments from EV drivers. By addressing key pain points, EV Advisor enables businesses and operators to effectively manage their networks, helping meet sustainability targets while creating a hassle-free experience for EV owners. EVAdvisor is available in the UK, Ireland, Denmark, France, Germany, Switzerland, and Austria, with plans for further expansion soon.

Charge to 80% in just 20 minutes

With nearly 90% of EV charging expected to take place in buildings, Schneider Electric also announced EVlink Pro DC, a fast-charging station for the commercial and industrial built environments. Scalable from 120kW to 180kW, EVlink Pro DC maximizes energy efficiency and minimizes electrical costs through dynamic power allocation. This balances the amount of energy delivered to each vehicle according to need, reducing power loss across charging stations. The EVlink Pro DC 180kW enables vehicles to reach 80%ⁱ charge in only 20 minutes, optimizing energy use and shortening the time needed to get fleet vehicles back on the road.

EV Link Pro DC will be available throughout Europe, as well as the Middle East, Africa, APAC and East Asia, by the end of the year.

State-of-the-art home EV charging

Schneider Charge, a smart EV charging station for homes, has been designed with ease of use, flexibility, safety, and efficiency in mind. With only just over half (51%) of EV owners worldwide having a charger at home, Schneider Charge offers a solution that is robust, cost-effective and simple to install.

Through remote operation through the Wiser mobile app, or other EV charging apps, users can easily schedule, monitor and adapt charging times while taking advantage of dynamic tariffs to intuitively charge when electricity rates are lower. Schneider Charge also offers peace of mind with an anti-trip system, allowing EV charging without overloading or disrupting power supply.

Schneider Charge will be made available throughout Europe, as well as Australia, New Zealand and parts of Asia by the end of the year. 

Skilled labour, from start to finish

Reliable charging infrastructure is critical to accelerating EV adoption, but it requires skilled labor to install and maintain it. Today Schneider Electric also announced the expansion of its North America partner, Qmerit, the leading provider of distributed workforce management for EV charging, to European markets. Qmerit will connect customers with a network of expert professional installers, providing on-site support to ensure easy setup of charging infrastructure. This will strengthen Schneider Electric’s worldwide network of technicians who are committed to improving the performance of EV infrastructure and keeping assets running safely and efficiently.

“We’re delighted to launch our eMobility solutions for faster, more reliable and convenient EV charging both at home and on the go”, said Nadège Petit, Schneider Electric’s Chief Innovation Officer. “Our new open platform software, EV Advisor, in conjunction with our EVlink Pro DC chargers, means operators can now benefit from a fully integrated solution to manage their networks.  This helps them maintain uptime, removing EV drivers’ concerns about charge station reliability while on the road. Schneider Charge increases convenience for EV owners even further, bringing the full potential of EV charging to the home.”

“Solutions like these are vital to addressing the biggest challenges to EV adoption, such as fast and reliable charging, and the management, control and installation of infrastructure. As demand for charging stations rises with the uptake of EVs, it has never been more important that our customers ‘stay in the driving seat’ when it comes to managing their own infrastructure.”

ⁱ Dependent on battery size and vehicle specifications.
 

Contact:
Schneider Electric Global Media Relations
global.pr@se.com

Attachment

• Press Release_IS_Schneider Electric accelerates the EV transition with faster, smarter, more reliable charging solutions.pdf

“We are very pleased to be expanding our partnership with ARYZE to now include the digital representation of two more of the world’s premier currencies. We view ARYZE Digital Cash as a great example of the benefits of cutting edge Web3 finance bringing as it does total protection and security for safe storage of value using pioneering technology,” highlights Fabrício Tota, MB’s Director of New Business.

Jack Nikogosian, ARYZE CEO, commented: “We are thrilled to broaden our Digital Cash stablecoins’ footprint with Mercardo Bitcoin. Their community can now not only transact and invest in leading global currencies but also swiftly swap between Digital Cash currency pairs with unparalleled ease, thanks to our innovative structure. Our stablecoins serve as a safe store of value and a hedge against inflation, simplifying and enriching financial livelihoods.”

Digital Cash operates consistently with a full reserve backing model, mitigating bank and counterparty risk and is over-collateralized. Digital Cash is unique amongst stablecoins as cross currency conversion is embedded into the fabric of every coin bringing previously unseen fungibility between major currency pairs and making Aryze Digital Cash globally relevant.

About Mercado Bitcoin (MB): Mercado Bitcoin is the largest cryptocurrency and alternative asset trading platform in Latin America, as well as Brazil’s first crypto unicorn. The company is a member of the Brazilian Association of Cryptoeconomics (ABCripto) and adheres to the Code of Conduct and Self-Regulation in Money Laundering Prevention developed by the association.

About ARYZE: ARYZE is a multinational FinTech business dedicated to resolving global financial challenges and advancing financial inclusion for the unbanked population worldwide. ARYZE accomplishes this goal together with its strategic partners by offering a suite of proprietary blockchain-based products and services, including Digital Cash stablecoins & the native RYZE token issued by ARYZE BVI. Aryze is a registered Virtual Assets Service Provider (VASP) with the Danish Financial Service Authority.

Contact:
Jack Nikogosian
CEO at ARYZE
jn@aryze.io

CallTower’s Cisco Webex solution with CT Text delivers both MMS and SMS capabilities translated in over 60 languages ensuring ease of contact and conversation searching within the Webex client and simplifying communications. Utilizing the same number used for voice calls, CT Text maximizes reach and impact of SMS and MMS users within Webex by Cisco by enabling individuals to text directly from their voice number or a group shared phone number. CT Text further enhances global communication strategies with features like group texting and text translation for over 60 languages. 

“We are thrilled to have launched this addition to CallTower’s Webex solution,” cited CallTower Chief Revenue Officer William Rubio. “With both MMS and SMS CT Text integrations available in over 60 languages, users can communicate via one central platform, instead of sending texts from a cell phone or a third-party application. The result of this integration translates into improved communications with customers, supplemented with the increased security associated with a safe and secure single interaction platform.” 

As a Cisco Partner since 2002, CallTower completed a rigorous certification process to ensure end-to-end compatibility with Webex solutions. Most recently, CallTower earned the Cisco Powered Premiere Provider Worldwide designation. This in-depth process ensures that customers receive consistently high-quality and reliable services from Cisco Certified Calling Providers. Customers can be confident that CallTower supports a wide range of Webex deployments, including basic calling scenarios, enterprise-scale Webex Calling, Webex Dedicated Instance migrations, and demanding high-volume Webex Contact Center deployments. 

About CallTower 

 Since its inception in 2002, CallTower has evolved into a global cloud-based, enterprise-class Unified Communications, Contact Center, and Collaboration solutions provider for growing organizations worldwide. CallTower provides, integrates, and supports industry-leading solutions, including Operator Connect for Microsoft® Teams, MS Teams Direct Routing, GCC High Teams Direct Routing, Microsoft® 365, Cisco® Webex Calling / UCM, Cisco® CCP, Zoom Phone, Zoom (BYOB) and four contact center options, including Five9 for business customers. 

For more information, contact marketing@calltower.com 

Previously a Partner and senior member of the global life sciences practice at L.E.K. Consulting, a global strategy consulting firm, and co-head and representative director of L.E.K.’s Japan office, Mr. Branch brings extensive industry experience from directing strategic consulting projects for L.E.K.’s biopharma, medtech, healthcare and private equity clients. He has advised many executive teams across hundreds of engagements in Japan, APAC and the US on a range of business-critical issues, including growth strategy, business development and M&A, commercial strategy and operations, pricing and market access, and organizational design.

Mr. Branch holds an MBA from INSEAD (Fontainebleau, France) and a Masters of Public Health (MPH) from Columbia University, Mailman School of Public Health (New York, USA). He also holds degrees from the University of Nottingham (Nottingham, UK) and SOAS, University of London (London, UK).

Chris Cargill, CEO and President of Nxera Pharma, commented: “I’m delighted to welcome Patrick to the business development team at Nxera. This important appointment further demonstrates our commitment to advancing and growing our integrated Japan pharma business to develop and deliver more life-changing medicines for patients in the large and rapidly growing Japan and APAC markets. We believe both the challenges to and the lag in gaining new drug approvals in these markets represent major opportunities for our business for which we are strategically well positioned.”

Patrick Branch, Head of Business Development for Japan and APAC at Nxera Pharma, added: “Nxera is an emerging leader in the Japanese biopharma sector, and I am honored to be joining the Company at such a pivotal time. I look forward to contributing my experience to build on the existing strong foundations to drive growth and new opportunities for the business in Japan and APAC where, with our lean, go-to-market commercial model, we are well positioned to scale rapidly and generate significant value for patients and our major stakeholders.”

–END–

About Nxera Pharma
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.

In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWave^TM” platform to provide a sustainable source of best- or first-in-class candidates.

Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma

Enquiries:

Nxera Pharma – Media and Investor Relations
Kentaro Tahara, VP Investor Relations and Corporate Strategy
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Maya Bennison, Communications Manager
+81 (0)3 5210 3399 | +44 (0)1223 949390 | IR@Nxera.life

MEDiSTRAVA Consulting (for International Media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | Nxera@medistrava.com

Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.